ES2115096T3 - Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. - Google Patents

Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.

Info

Publication number
ES2115096T3
ES2115096T3 ES94106848T ES94106848T ES2115096T3 ES 2115096 T3 ES2115096 T3 ES 2115096T3 ES 94106848 T ES94106848 T ES 94106848T ES 94106848 T ES94106848 T ES 94106848T ES 2115096 T3 ES2115096 T3 ES 2115096T3
Authority
ES
Spain
Prior art keywords
compounds
tetrazolic
medicines
derivatives
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106848T
Other languages
English (en)
Spanish (es)
Inventor
Alfons Dr Enhsen
Heiner Dr Glombik
Werner Dr Dr Kramer
Gunter Dr Wess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2115096T3 publication Critical patent/ES2115096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES94106848T 1993-05-08 1994-05-02 Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. Expired - Lifetime ES2115096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315368 1993-05-08

Publications (1)

Publication Number Publication Date
ES2115096T3 true ES2115096T3 (es) 1998-06-16

Family

ID=6487579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106848T Expired - Lifetime ES2115096T3 (es) 1993-05-08 1994-05-02 Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.

Country Status (19)

Country Link
US (1) US5466815A (OSRAM)
EP (1) EP0624596B1 (OSRAM)
JP (1) JP3476157B2 (OSRAM)
KR (1) KR100333149B1 (OSRAM)
AT (1) ATE163938T1 (OSRAM)
AU (1) AU666440B2 (OSRAM)
CA (1) CA2123048C (OSRAM)
CY (1) CY2119B1 (OSRAM)
CZ (1) CZ289515B6 (OSRAM)
DE (1) DE59405410D1 (OSRAM)
DK (1) DK0624596T3 (OSRAM)
ES (1) ES2115096T3 (OSRAM)
FI (1) FI942075A7 (OSRAM)
GR (1) GR3026496T3 (OSRAM)
HU (1) HU217439B (OSRAM)
IL (1) IL109581A (OSRAM)
NO (1) NO304795B1 (OSRAM)
NZ (1) NZ260469A (OSRAM)
TW (1) TW289757B (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (OSRAM) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
CA2372493A1 (en) 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
US7086134B2 (en) * 2000-08-07 2006-08-08 Shipley Company, L.L.C. Alignment apparatus and method for aligning stacked devices
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1392713B1 (en) * 2001-05-03 2007-10-17 The University of Chicago Liver x receptor agonists
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US6816317B2 (en) * 2002-01-31 2004-11-09 Lightel Technologies Inc. Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
EP2289560B1 (en) * 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
EP2459581A4 (en) * 2009-07-29 2012-12-26 Univ Chicago LIVER X-RECEPTOR AGONISTS
JP5889321B2 (ja) 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のibat阻害剤
WO2012064267A1 (en) 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Eaファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) * 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Fxr/tgr5アゴニストとしての胆汁酸類似体およびその使用方法
MX2017010376A (es) * 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN111116699B (zh) * 2015-04-28 2023-02-28 江苏豪森药业集团有限公司 胆酸衍生物及其制备方法和医药用途
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
KR102499441B1 (ko) 2016-11-29 2023-02-13 이난타 파마슈티칼스, 인코포레이티드 술포닐우레아 담즙산 유도체의 제조 방법
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
EP3921027B1 (en) 2019-02-06 2023-07-19 Albireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
JP7044948B1 (ja) * 2019-03-19 2022-03-30 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
TWI865673B (zh) 2019-12-04 2024-12-11 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Asbt阻害剤の皮下投与
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20250368678A1 (en) * 2022-06-09 2025-12-04 Shandong Luye Pharmaceutical Co., Ltd. 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same
JP2025521736A (ja) 2022-07-05 2025-07-10 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2025119319A1 (zh) * 2023-12-08 2025-06-12 山东绿叶制药有限公司 一种gabaa受体调节剂的晶型及其制备方法和应用
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
FI106800B (fi) * 1990-12-06 2001-04-12 Hoechst Ag Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi

Also Published As

Publication number Publication date
NZ260469A (en) 1995-03-28
US5466815A (en) 1995-11-14
CA2123048C (en) 2005-11-29
TW289757B (OSRAM) 1996-11-01
HU9401443D0 (en) 1994-08-29
KR100333149B1 (ko) 2002-09-19
IL109581A0 (en) 1994-08-26
NO941677L (no) 1994-11-09
CZ113594A3 (en) 1994-12-15
CY2119B1 (en) 2002-04-26
DE59405410D1 (de) 1998-04-16
FI942075A0 (fi) 1994-05-05
JP3476157B2 (ja) 2003-12-10
CA2123048A1 (en) 1994-11-09
FI942075L (fi) 1994-11-09
AU666440B2 (en) 1996-02-08
AU6194794A (en) 1994-11-10
HUT67390A (en) 1995-04-28
EP0624596A2 (de) 1994-11-17
IL109581A (en) 1998-03-10
EP0624596A3 (de) 1995-06-07
NO941677D0 (no) 1994-05-06
JPH06329695A (ja) 1994-11-29
HU217439B (hu) 2000-01-28
EP0624596B1 (de) 1998-03-11
DK0624596T3 (da) 1998-10-07
ATE163938T1 (de) 1998-03-15
FI942075A7 (fi) 1994-11-09
GR3026496T3 (en) 1998-07-31
NO304795B1 (no) 1999-02-15
CZ289515B6 (cs) 2002-02-13

Similar Documents

Publication Publication Date Title
ES2115096T3 (es) Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2136677T3 (es) Derivados monomeros de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
ATE40994T1 (de) L-n-n-propylpipekolsaeure-2,6-xylidid und dessen herstellung.
MX9203677A (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
YU56995A (sh) Soli derivata indola
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
ATE235459T1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
MX9203264A (es) Nuevos derivados de la tieno(3,2-c)piridina y composiciones farmaceuticas que los contienen.
BR9912109A (pt) Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratar um mamìfero sofrendo de inflamação patológica e autoimunidade
ES2082755T3 (es) Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios.
NO932120L (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
ES8103170A1 (es) Un procedimiento para obtener una sustancia antibiotica
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES2044901T3 (es) Procedimiento para la preparacion de un derivado de imidazol y su utilizacion.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2054738T3 (es) Derivados de acido 3-desmetil-4-fluoromevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su empleo y productos intermedios.
MX9301723A (es) Derivados de carbinol di-arilo puenteados, composiciones y metodos de uso.
AR248394A1 (es) Procedimiento para obtener nuevos derivados de la n-bencilpiridina.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624596

Country of ref document: ES